FDA Drug Label
WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information
Novo Nordisk. FDA Drug Label. 2021
Compare
Semaglutide vs BPC-157
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
863 users report co-tracking this pair (230% of Semaglutide trackers also track BPC-157).
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Semaglutide
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 4% · Mixed 96% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
122
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
117
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
32
0.2–0.4 mg
5
0.4–0.6 mg
4
0.6–1 mg
9
1–2 mg
33
2–3 mg
34
5+ mg
5
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 94 days · Based on 23 repeat reporters
BPC-157
128 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
247
Energy
2
Sleep
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
5
Inflammation
1
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
2
0.025–0.05 mg
1
0.1–0.2 mg
3
0.2–0.4 mg
138
0.4–0.6 mg
94
0.6–1 mg
5
1–2 mg
1
3–5 mg
1
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 94% said they felt similar to their last entry, 6% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 50 days · Based on 47 repeat reporters
Sources (18)
Published sources linked on the Semaglutide and BPC-157 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
FDA Drug Label
OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information
Novo Nordisk. FDA Drug Label. 2017
- Wiki study page →Source
PubMed
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021
- Wiki study page →Source
ClinicalTrials.gov
Semaglutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Once-Weekly Semaglutide in Adolescents with Obesity.
Weghuber D, Barrett T, Barrientos-Pérez M, et al. N Engl J Med. 2022
- Wiki study page →Source
PubMed
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. N Engl J Med. 2023
- Wiki study page →Source
PubMed
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Wharton S, Calanna S, Davies M, et al. Diabetes Obes Metab. 2022
- Wiki study page →Source
PubMed
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. The New England journal of medicine. 2023
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
- Wiki study page →Source
PubMed
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts
Chang CH, Tsai WC, Lin MS, et al. Molecules. 2019
- Wiki study page →Source
PubMed
BPC 157 and its role in accelerating wound healing
Vukojevic J, Siroglavic M, Kasnik K, et al. Int J Mol Sci. 2022
- Wiki study page →Source
ClinicalTrials.gov
BPC-157 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
Seiwerth S, Rucman R, Turkovic B, et al. Current pharmaceutical design. 2018
- Wiki study page →Source
PubMed
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions
Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011
- Wiki study page →Source
PubMed
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Lee E, Padgett B. Altern Ther Health Med. 2021
- Wiki study page →Source
PubMed
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management
Yuan C, Demers A, Silva-Ortiz V, et al. Int J Mol Sci. 2026
- Wiki study page →Source
PubMed
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026
- Wiki study page →Source
PubMed
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026